On March 15, OrbiMed Advisors increased its stake in RAPT Therapeutics by 556,273 shares during the fourth quarter. RAPT Therapeutics was acquired for $58 per share. Prior to the acquisition, OrbiMed's stake in the company was valued at approximately $56 million.
